The size of the Lung Cancer Surgery Market in the Middle East & Africa is estimated to reach USD 3.70 billion by 2027 from a market value of USD 2.92 billion in 2022, growing at a CAGR of 4.9% between 2022 to 2027.
Lung Cancer is Cancer that starts in the lungs or trachea or bronchus. Lung Cancer can be treated by various methods like Chemotherapy, Radiotherapy, Laser therapy, and Surgery. Surgery involves the removal of the infected sections from the lungs. There are many types of Lung Cancer Surgery like Lobectomy, Pneumonectomy, Sleeve Resection, and Segmentectomy.
Rising pollution levels, an increasing number of cigarette smokers, rising incidence and prevalence of Lung Cancer and rising geriatric population are some of the major factors driving the market.
However, high cost of Lung Cancer surgery is restraining the growth of the market.
This research report on the Middle East and Africa Lung Cancer Surgery Market has been segmented & sub-segmented into the following categories:
On the basis of procedure, the Minimally Invasive surgeries are expected to grow at highest CAGR owing to the rising awareness among people for early detection of lung cancer and advantages of Minimally Invasive Surgeries over conventional surgeries.
On the basis of the device, the Surgical Instruments segment is expected to dominate the market owing to the shorter lifespan of devices and wider adoption of these devices.
Leading companies in the MEA Lung Cancer Surgery Market include Ethicon US LLC, Intuitive Surgical Inc., AngioDynamics Inc., Olympus Corporation, Accuray Inc., Ackermann Instrumente GmbH, Teleflex Inc., KARL STORZ GmbH, Scanlan International Inc., and Trokamed GmbH.
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: email@example.com